Consun Pharmaceutical Group Ltd
HKEX:1681
Income Statement
Earnings Waterfall
Consun Pharmaceutical Group Ltd
Revenue
|
2.6B
CNY
|
Cost of Revenue
|
-668.4m
CNY
|
Gross Profit
|
1.9B
CNY
|
Operating Expenses
|
-1B
CNY
|
Operating Income
|
885.8m
CNY
|
Other Expenses
|
-101.3m
CNY
|
Net Income
|
784.5m
CNY
|
Income Statement
Consun Pharmaceutical Group Ltd
Dec-2013 | Jun-2014 | Dec-2014 | Jun-2015 | Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
572
N/A
|
664
+16%
|
731
+10%
|
798
+9%
|
831
+4%
|
896
+8%
|
1 223
+37%
|
1 541
+26%
|
1 660
+8%
|
1 760
+6%
|
1 844
+5%
|
1 916
+4%
|
1 728
-10%
|
1 553
-10%
|
1 753
+13%
|
1 874
+7%
|
2 045
+9%
|
2 152
+5%
|
2 340
+9%
|
2 466
+5%
|
2 590
+5%
|
|
Gross Profit | ||||||||||||||||||||||
Cost of Revenue |
(120)
|
(140)
|
(159)
|
(165)
|
(161)
|
(179)
|
(312)
|
(405)
|
(432)
|
(462)
|
(460)
|
(496)
|
(467)
|
(407)
|
(431)
|
(462)
|
(517)
|
(547)
|
(577)
|
(605)
|
(668)
|
|
Gross Profit |
452
N/A
|
524
+16%
|
572
+9%
|
633
+11%
|
671
+6%
|
717
+7%
|
911
+27%
|
1 136
+25%
|
1 228
+8%
|
1 298
+6%
|
1 384
+7%
|
1 420
+3%
|
1 261
-11%
|
1 146
-9%
|
1 322
+15%
|
1 411
+7%
|
1 527
+8%
|
1 604
+5%
|
1 763
+10%
|
1 861
+6%
|
1 922
+3%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(246)
|
(301)
|
(336)
|
(356)
|
(377)
|
(387)
|
(512)
|
(646)
|
(695)
|
(719)
|
(729)
|
(747)
|
(765)
|
(728)
|
(772)
|
(821)
|
(867)
|
(933)
|
(1 048)
|
(1 083)
|
(1 036)
|
|
Selling, General & Administrative |
(256)
|
(315)
|
(345)
|
(362)
|
(382)
|
(392)
|
(516)
|
(656)
|
(704)
|
(726)
|
(738)
|
(757)
|
(771)
|
(733)
|
(775)
|
(827)
|
(882)
|
(954)
|
(1 062)
|
(1 093)
|
(1 155)
|
|
Other Operating Expenses |
10
|
14
|
9
|
5
|
5
|
6
|
4
|
10
|
9
|
7
|
9
|
9
|
6
|
5
|
4
|
6
|
15
|
20
|
14
|
10
|
119
|
|
Operating Income |
207
N/A
|
223
+8%
|
235
+6%
|
277
+17%
|
294
+6%
|
330
+12%
|
399
+21%
|
490
+23%
|
533
+9%
|
580
+9%
|
655
+13%
|
672
+3%
|
496
-26%
|
418
-16%
|
550
+32%
|
590
+7%
|
660
+12%
|
671
+2%
|
715
+7%
|
778
+9%
|
886
+14%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
4
|
16
|
29
|
32
|
22
|
12
|
6
|
5
|
12
|
(9)
|
(38)
|
(39)
|
(36)
|
(22)
|
34
|
56
|
38
|
30
|
32
|
37
|
(21)
|
|
Non-Reccuring Items |
(1)
|
0
|
(0)
|
(2)
|
(2)
|
(1)
|
(2)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(326)
|
(326)
|
(0)
|
(0)
|
(2)
|
(3)
|
(1)
|
(0)
|
(1)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
211
N/A
|
239
+13%
|
264
+11%
|
307
+16%
|
315
+3%
|
341
+8%
|
403
+18%
|
494
+23%
|
545
+10%
|
570
+5%
|
617
+8%
|
632
+3%
|
134
-79%
|
70
-48%
|
584
+738%
|
646
+11%
|
696
+8%
|
698
+0%
|
746
+7%
|
814
+9%
|
864
+6%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
(58)
|
(54)
|
(53)
|
(66)
|
(65)
|
(68)
|
(84)
|
(121)
|
(123)
|
(112)
|
(119)
|
(110)
|
(71)
|
(69)
|
(102)
|
(116)
|
(109)
|
(60)
|
(63)
|
(79)
|
(77)
|
|
Income from Continuing Operations |
153
|
185
|
211
|
242
|
250
|
274
|
320
|
373
|
422
|
458
|
497
|
522
|
63
|
0
|
482
|
529
|
587
|
638
|
684
|
736
|
787
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
(12)
|
(26)
|
(26)
|
(28)
|
(32)
|
(26)
|
17
|
39
|
17
|
11
|
3
|
(2)
|
(1)
|
(2)
|
(2)
|
|
Net Income (Common) |
153
N/A
|
185
+21%
|
211
+14%
|
242
+14%
|
250
+3%
|
274
+10%
|
308
+12%
|
347
+13%
|
396
+14%
|
430
+9%
|
465
+8%
|
496
+7%
|
80
-84%
|
39
-51%
|
499
+1 171%
|
541
+8%
|
590
+9%
|
636
+8%
|
683
+7%
|
734
+7%
|
785
+7%
|
|
EPS (Diluted) |
0.2
N/A
|
0.18
-10%
|
0.21
+17%
|
0.24
+14%
|
0.25
+4%
|
0.28
+12%
|
0.32
+14%
|
0.38
+19%
|
0.46
+21%
|
0.51
+11%
|
0.53
+4%
|
0.56
+6%
|
0.09
-84%
|
0.05
-44%
|
0.61
+1 120%
|
0.67
+10%
|
0.73
+9%
|
0.79
+8%
|
0.86
+9%
|
0.93
+8%
|
0.98
+5%
|